Why Asia?
- Quality:
- - ICH-GCP has been implemented and adopted since 1997
- - Successful completion of global IND trials for US NDAs
- - Enthusiastic and qualified clinical trial professionals
- Speed:
- - Large pool of patients with wide spectrum of diseases
- - Favorable review timeline (3-4 months)
- - Cluster and Joint IRBs serve as simple process of application and review
- Cost:
- - Considerably low cost compared with US and Europe
- Market potential:
- - One of the fast growing drug markets in the world
- - Technology transfer
- Administration:
- - Effective English capability
- - Comprehensive project management
- - Homogeneous and well-connected logistics for sample transportation